Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
This article was originally published in The Pink Sheet Daily
Executive Summary
OTC Allegra could soon face competition from private-label fexofenadine marketed by Perrigo, which acquired U.S. rights from ANDA-filer Teva.
You may also be interested in...
Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report
Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.
Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report
Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Perrigo is "poised for some significant growth" with $180 million in new product sales expected in the firm's current fiscal year, according to President and CEO Joseph Papa.